Boca Trim SLU-PP-332

Background

Boca Trim SLU-PP-332 is an exercise mimetic compound that replicates a state of physical activity in the body by activation of specific proteins recruited during normal exercise. [18] The compound targets metabolic pathways and future development has implications for treating metabolic and neurodegenerative diseases coupled with anti-aging potential associated with promotion of lean muscle mass. [19] Furthermore, the compound amplifies energy balance in skeletal muscle cells leading to improved physical performance. [19] Based on the compound's observed actions as an exercise mimetic, the simulated increase in physical activity may also lead to a viable weight-loss adjunct. [20]

The health benefits of physical exercise are universally accepted based on promotion of positive physical adaptations. [1] SLU-PP-332 is classified as an estrogen receptor-related orphan receptor (ERR) agonist that has exercise mimetic actions and could be promising treatment for metabolic diseases based on fat mass reduction capabilities. [1] In other words, this substance has been shown to initiate positive processes in the body resembling those activated by physical activity. [6] Additionally, the compound flips a switch in the body to initiate an exercise state, promoting increases in energy levels, decrease in fat storage coupled with enhanced insulin sensitivity. [6] Although the physical activity of exercise is irreplaceable, leading researchers suggest the compound could substitute in certain cases or amplify effects in normal situations. [7] The suggested mimetic effects include exercise's ability to boost muscle cells' metabolism and growth coupled with increased muscle performance output, resulting in benefits for both mind and body. [7] Put simply, SLU-PP-332 communicates to skeletal muscle to make the adjustments necessary for endurance training, whether in a sedentary state or an amplified environment if engaged in actual physical activity. [17]

Research

It is important to provide a definition of Metabolic syndrome (MetS), a collection of interrelated metabolic disorders, e.g., elevated blood lipid levels, hypertension, insulin resistance, and obesity, which increase risk of cardiovascular disease and type 2 diabetes. [8] It is well known that MetS is on the rise worldwide which has compounded the need for tools to support, or supplement lifestyle changes such as innovative interventions like SLU-PP-332. [8] There is a substantive history of treatment approaches for reduction in MetS cases. As previously noted, SLU-PP-332 is an estrogen receptor-related orphan receptor (ERR) agonist with a mechanism of action as an exercise mimetic. [1] Treating MetS has many components which may all need to be addressed to effectively mitigate MetS. [9] Other MetS therapeutic treatments function as insulin sensitizers to improve insulin sensitivity, there are lipid-lowering medications known as statins, compounds associated with attenuating blood lipid levels, and antihypertensive agents like ACE inhibitors. [10-14] The outcome to effectively treat MetS is to explore multiple pathways to develop comprehensive treatment protocols. [15]

SLU-PP-332 is a synthetic estrogen receptor-related orphan receptor (ERR) agonist with exercise simulation, e.g., mimetic properties which may be effective to treat metabolic diseases by attenuating fat mass. [1] Recurring physical exercise promotes positive adaptations in the body that both upgrade future performance and serve as preventative treatment against several diseases. [2] SLU-PP-332, the synthetic ERR pan agonist, has demonstrated target efficacy to all three ERR subtypes (ERRα, β, and γ), enhancing cellular respiration and mitochondrial function in the skeletal muscle cell line. [2] Novel ERR pan agonists may also have cardioprotective properties as demonstrated in a recent study that established that estrogen-related receptors can ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. [3] Two of the ERR subtypes, the ERRα and ERRγ isoforms, appear to play a significant role in moderating cellular energy metabolism and metabolic genes. [4] In other words, they function as growth and metabolism factors while also holding predictive power over pathways in health and disease, e.g., metabolic diseases and related conditions. [4] ERRs have a key role in antioxidant protection, cardiac function, and metabolism, factors associated with enhanced exercise endurance output, due in part to abilities to encourage autophagy, or a natural breakdown and recycling process that regulates cellular homeostasis. [2, 5]

Conclusion

SLU-PP-332 is classified as an estrogen receptor-related orphan receptor (ERR) agonist that has exercise mimetic actions and could be promising treatment for metabolic syndrome based on fat mass reduction capabilities. [1] Put simply, while there is no substitute for the health benefits associated with actual exercise, this compound simulates a state of physical activity in the body by acting on proteins that engage in muscle growth and metabolism. [16] The exercise mimetic compound has a mechanism of action through estrogen-related receptors activation necessary for muscle growth and metabolism. [16] ERRs are robustly expressed in tissues associated with high energy needs, e.g., brain, heart, kidneys, liver, skeletal muscle, and both brown and white adipose tissue. [17] In other words, it makes sense that SLU-PP-332 intake would target fueling to areas of the body that can utilize it most. [17] The compound also has actions as a mitochondrial enhancer, or the powerhouse of the cell that produces adenosine triphosphate (ATP) through aerobic respiration, responsible for simulating exercise activity. [17]

References

[1] Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024 Jan 17;388(2):232-240. doi: 10.1124/jpet.123.001733. PMID: 37739806; PMCID: PMC10801787.

[2] Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, Kazantzis M, Chatterjee A, Chrivia J, Hayes ME, Xu W, Hamilton A, Huss JM, Zhang L, Walker JK, Downes M, Evans RM, Burris TP. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023 Apr 21;18(4):756-771. doi: 10.1021/acschembio.2c00720. Epub 2023 Mar 29. PMID: 36988910; PMCID: PMC11584170.

[3] Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, Rideb JRDC, Zhao Y, Hayes M, Yu K, Losby M, Hampton CS, Adeyemi CM, Hong SJ, Nasiotis E, Fu C, Oh TG, Fan W, Downes M, Welch RD, Evans RM, Milosavljevic A, Walker JK, Jensen BC, Pei L, Burris T, Zhang L. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024 Jan 16;149(3):227-250. doi: 10.1161/CIRCULATIONAHA.123.066542. Epub 2023 Nov 14. PMID: 37961903; PMCID: PMC10842599.

[4] Huss JM, Garbacz WG, Xie W. Constitutive activities of estrogen-related receptors: Transcriptional regulation of metabolism by the ERR pathways in health and disease. Biochim Biophys Acta. 2015 Sep;1852(9):1912-27. doi: 10.1016/j.bbadis.2015.06.016. Epub 2015 Jun 24. PMID: 26115970.

[5] Losby M, Hayes M, Valfort A, Sopariwala DH, Sanders R, Walker JK, Xu W, Narkar VA, Zhang L, Billon C, Burris TP. The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB. Mol Pharmacol. 2024 Sep 17;106(4):164-172. doi: 10.1124/molpharm.124.000889. PMID: 39168657; PMCID: PMC11413914.

[6] Cross, P. I., & Seladi-Schulman, J. (2023, September 29). New drug may help lose weight, reduce fat by mimicking exercise. https://www.medicalnewstoday.com/articles/new-drug-may-help-lose-weight-reduce-fat-by-mimicking-exercise.

[7] PressPacs. (2024, March 18). Mimicking exercise with a pill. https://www.acs.org/pressroom/presspacs/2024/march/mimicking-exercise-with-a-pill.html.

[8] Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., ... & Smith Jr, S. C. (2009). Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. *Circulation*, *120*(16), 1640-1645.

[9] Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev. 2008 Dec;29(7):777-822. doi: 10.1210/er.2008-0024. Epub 2008 Oct 29. PMID: 18971485; PMCID: PMC5393149.

[10] Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr. 2002;22:167-97. doi: 10.1146/annurev.nutr.22.010402.102808. Epub 2002 Jan 4. PMID: 12055342.

[11] Bjornstad, P., Schäfer, M., Truong, U., Cree-Green, M., Pyle, L., Baumgartner, A., ... & Nadeau, K. J. (2018). Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus: randomized controlled trial. *Circulation*, *138*(25), 2895-2907.

[12] Clark LT. Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J. 2003 Mar;145(3):387-96. doi: 10.1067/mhj.2003.70. PMID: 12660659.

[13] Pasta, A., Cremonini, A. L., Pisciotta, L., Buscaglia, A., Porto, I., Barra, F., ... & Rosa, G. M. (2020). PCSK9 inhibitors for treating hypercholesterolemia. *Expert opinion on pharmacotherapy*, *21*(3), 353-363.

[14] Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. Epub 2020 May 6. PMID: 32370572.

[15] Ross GR. Conquering Metabolic Syndrome: Navigating Pharmacological Avenues for Comprehensive Therapeutics. J Pharmacol Exp Ther. 2024 Jan 17;388(2):229-231. doi: 10.1124/jpet.123.001908. PMID: 38233228.

[16] Abbott, E. (2024, March 18). Exercise in a Pill? Breakthrough Mimics Workout Benefits. https://neurosciencenews.com/exercise-pill-neuroscience-25767.

[17] Campbell, J. (2024, October 5). SLU-PP-332: The G.O.A.T. Of All Fat Loss Agents? https://jaycampbell.com/fat-loss/slu-pp-332.

[18] Felstead, Scott ‘Future’. (2024). A New Drug SLU-PP-332 Mimics The Effects of Exercise In the Body. https://www.muscleandfitness.com/features/feature-news/a-new-drug-slu-pp-332-mimics-the-effects-of-exercise-in-the-body.

[19] Cassella, C. (2024, March 22). New “Exercise Pill” Could Induce Fitness Benefits Without Exercise. https://www.sciencealert.com/new-exercise-pill-could-induce-fitness-benefits-without-exercise.

[20] Hamilton, E. (2023, September 27). Exercise-mimicking drug sheds weight, boosts muscle activity in mice. https://www.news.ufl.edu/2023/09/exercise-mimicking-drug.

Summary

Boca Trim SLU-PP-332 is a compound that mimics a state of physical activity in the body by activation of specific proteins recruited during exercise. The compound targets metabolic pathways and future development has implications for metabolic and neurodegenerative diseases coupled with anti-aging potential associated with promotion of lean muscle mass. SLU-PP-332 is classified as an estrogen receptor-related orphan receptor (ERR) agonist that has exercise mimetic actions and could be promising treatment for metabolic diseases based on fat mass reduction capabilities. The health benefits of physical exercise are universally accepted based on promotion of positive physical adaptations. This novel compound could offer an alternative for patients unable to participate in normal physical activity based on age, disease, or other conditions, additionally as a weight-loss adjunct associated with exercise mimetic properties.